Generalization and representativeness of phase III immune checkpoint blockade trials in non‐small cell lung cancer

Abstract

Only 30% of NSCLC patients were eligible for ICB phase III trials. The actual efficacy in the 70% of ineligible patients is unknown. These findings suggest a huge gap between practice-changing phase III trials and the overall population of NSCLC patients.